<?xml version='1.0' encoding='utf-8'?>
<document id="28848011"><sentence text="Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran."><entity charOffset="71-80" id="DDI-PubMed.28848011.s1.e0" text="Ritonavir" /><entity charOffset="190-200" id="DDI-PubMed.28848011.s1.e1" text="Dabigatran" /><pair ddi="false" e1="DDI-PubMed.28848011.s1.e0" e2="DDI-PubMed.28848011.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28848011.s1.e0" e2="DDI-PubMed.28848011.s1.e1" /></sentence><sentence text="Dabigatran etexilate (DE) is a P-glycoprotein (P-gp) probe substrate, and its active anticoagulant moiety, dabigatran, is a substrate of the multidrug and toxin extrusion protein-1 (MATE-1) transporter"><entity charOffset="0-20" id="DDI-PubMed.28848011.s2.e0" text="Dabigatran etexilate" /><entity charOffset="22-24" id="DDI-PubMed.28848011.s2.e1" text="DE" /><entity charOffset="107-117" id="DDI-PubMed.28848011.s2.e2" text="dabigatran" /><pair ddi="false" e1="DDI-PubMed.28848011.s2.e0" e2="DDI-PubMed.28848011.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28848011.s2.e0" e2="DDI-PubMed.28848011.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28848011.s2.e0" e2="DDI-PubMed.28848011.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28848011.s2.e1" e2="DDI-PubMed.28848011.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28848011.s2.e1" e2="DDI-PubMed.28848011.s2.e2" /></sentence><sentence text=" The antiretroviral pharmacokinetic enhancers, ritonavir and cobicistat, inhibit both these transporters"><entity charOffset="47-56" id="DDI-PubMed.28848011.s3.e0" text="ritonavir" /></sentence><sentence text=" Healthy volunteers received single doses of DE at 150 mg alone, followed by ritonavir at 100 mg or cobicistat at 150 mg daily for 2 weeks"><entity charOffset="77-86" id="DDI-PubMed.28848011.s4.e0" text="ritonavir" /><entity charOffset="45-53" id="DDI-PubMed.28848011.s4.e1" text="DE" /><pair ddi="false" e1="DDI-PubMed.28848011.s4.e1" e2="DDI-PubMed.28848011.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28848011.s4.e1" e2="DDI-PubMed.28848011.s4.e0" /></sentence><sentence text=" DE was then given 2 h before ritonavir or cobicistat"><entity charOffset="30-39" id="DDI-PubMed.28848011.s5.e0" text="ritonavir" /><entity charOffset="43-53" id="DDI-PubMed.28848011.s5.e1" text="cobicistat" /><entity charOffset="1-10" id="DDI-PubMed.28848011.s5.e2" text="DE" /><pair ddi="false" e1="DDI-PubMed.28848011.s5.e2" e2="DDI-PubMed.28848011.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28848011.s5.e2" e2="DDI-PubMed.28848011.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28848011.s5.e2" e2="DDI-PubMed.28848011.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28848011.s5.e0" e2="DDI-PubMed.28848011.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28848011.s5.e0" e2="DDI-PubMed.28848011.s5.e1" /></sentence><sentence text=" One week later, DE was given simultaneously with ritonavir or cobicistat"><entity charOffset="50-59" id="DDI-PubMed.28848011.s6.e0" text="ritonavir" /><entity charOffset="63-73" id="DDI-PubMed.28848011.s6.e1" text="cobicistat" /><entity charOffset="17-26" id="DDI-PubMed.28848011.s6.e2" text="DE" /><pair ddi="false" e1="DDI-PubMed.28848011.s6.e2" e2="DDI-PubMed.28848011.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28848011.s6.e2" e2="DDI-PubMed.28848011.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28848011.s6.e2" e2="DDI-PubMed.28848011.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28848011.s6.e0" e2="DDI-PubMed.28848011.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28848011.s6.e0" e2="DDI-PubMed.28848011.s6.e1" /></sentence><sentence text=" No significant increases in dabigatran pharmacokinetic (PK) exposure or thrombin time (TT) measures were observed with the simultaneous administration of ritonavir"><entity charOffset="29-39" id="DDI-PubMed.28848011.s7.e0" text="dabigatran" /><entity charOffset="155-164" id="DDI-PubMed.28848011.s7.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.28848011.s7.e0" e2="DDI-PubMed.28848011.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28848011.s7.e0" e2="DDI-PubMed.28848011.s7.e1" /></sentence><sentence text=" Separated administration of ritonavir resulted in a mean decrease in dabigatran PK exposure of 29% (90% confidence interval [CI], 18 to 40%) but did not significantly change TT measures"><entity charOffset="29-38" id="DDI-PubMed.28848011.s8.e0" text="ritonavir" /></sentence><sentence text=" However, cobicistat increased dabigatran PK exposure (area under the concentration-versus-time curve from time zero to infinity and maximum plasma concentration) by 127% each (90% CI, 81 to 173% and 59 to 196%, respectively) and increased TT measures (33% for the area-under-the-effect curve from time zero to 24 h [90% CI, 22 to 44%] and 51% for TT at 24 h [90% CI, 22 to 78%]) when given simultaneously with dabigatran"><entity charOffset="411-421" id="DDI-PubMed.28848011.s9.e0" text="dabigatran" /></sentence><sentence text=" Similar increases were observed when cobicistat was administered separately by 2 h from the administration of dabigatran"><entity charOffset="111-121" id="DDI-PubMed.28848011.s10.e0" text="dabigatran" /></sentence><sentence text=" In all comparisons, no significant increase in the dabigatran elimination half-life was observed"><entity charOffset="52-62" id="DDI-PubMed.28848011.s11.e0" text="dabigatran" /></sentence><sentence text=" Therefore, it is likely safe to coadminister ritonavir with DE, while there is a potential need for reduced dosing and prudent clinical monitoring with the coadministration of cobicistat due to the greater net inhibition of intestinal P-gp transport and increased bioavailability"><entity charOffset="46-55" id="DDI-PubMed.28848011.s12.e0" text="ritonavir" /><entity charOffset="61-63" id="DDI-PubMed.28848011.s12.e1" text="DE" /><pair ddi="false" e1="DDI-PubMed.28848011.s12.e0" e2="DDI-PubMed.28848011.s12.e0" /><pair ddi="false" e1="DDI-PubMed.28848011.s12.e0" e2="DDI-PubMed.28848011.s12.e1" /></sentence><sentence text=" (This study has been registered at ClinicalTrials" /><sentence text="gov under identifier NCT01896622" /><sentence text=")" /><sentence text="" /></document>